Poliovirus Receptor Protein (PVR) (Transcript Variant 2)
Quick Overview for Poliovirus Receptor Protein (PVR) (Transcript Variant 2) (ABIN2713446)
Target
See all Poliovirus Receptor (PVR) ProteinsProtein Type
Origin
Source
Application
Purity
-
-
Protein Characteristics
- Transcript Variant 2
-
Characteristics
-
- Recombinant human CD155 / PVR (transcript variant 2) protein expressed in HEK293 cells.
- Produced with end-sequenced ORF clone
-
Endotoxin Level
- < 0.1 EU per μg protein as determined by LAL test
-
-
Want other Options for this Protein ?
!Discover Our Predefined Custom Proteins and Custom Protein Services!Your project requires further customization? Contact us and discover our custom protein solutions
-
-
-
Application Notes
-
Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays -
Restrictions
- For Research Use only
-
-
-
Concentration
- 50 μg/mL
-
Buffer
- 20 mM Phosphate buffer, 150 mM NaCl, pH 7.4. Avoid repeated freeze-thaw cycles. Stable for at least 3 months from receipt of products under proper storage and handling conditions.
-
Storage
- -80 °C
-
Storage Comment
- Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.
-
-
- Poliovirus Receptor (PVR)
-
Alternative Name
- Cd155,pvr
-
Background
- The protein encoded by this gene is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. The external domain mediates cell attachment to the extracellular matrix molecule vitronectin, while its intracellular domain interacts with the dynein light chain Tctex-1/DYNLT1. The gene is specific to the primate lineage, and serves as a cellular receptor for poliovirus in the first step of poliovirus replication. Multiple transcript variants encoding different isoforms have been found for this gene.
-
Molecular Weight
- 36.1 kDa
-
NCBI Accession
- NP_001129240
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Cancer Immune Checkpoints, SARS-CoV-2 Protein Interactome
Target
-